Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes.

[1]  S. Pocock,et al.  Primary and Secondary Outcome Reporting in Randomized Trials: JACC State-of-the-Art Review. , 2021, Journal of the American College of Cardiology.

[2]  X. Rosselló,et al.  Survival analyses in cardiovascular research, part II: statistical methods in challenging situations. , 2021, Revista espanola de cardiologia.

[3]  X. Rosselló,et al.  Survival analyses in cardiovascular research, part I: the essentials. , 2021, Revista espanola de cardiologia.

[4]  H. Schunkert,et al.  Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus. , 2020, JACC. Cardiovascular interventions.

[5]  H. Schunkert,et al.  Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes , 2020, Annals of Internal Medicine.

[6]  M. Price,et al.  Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score. , 2020, JACC. Cardiovascular interventions.

[7]  P. Serruys,et al.  The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial , 2020, Clinical Research in Cardiology.

[8]  W. Rottbauer,et al.  Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. , 2019, The New England journal of medicine.

[9]  Jason P. Fine,et al.  Statistical Primer for Cardiovascular Research Introduction to the Analysis of Survival Data in the Presence of Competing Risks , 2022 .

[10]  H. Suryapranata,et al.  Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor , 2015, Journal of cardiovascular pharmacology.

[11]  M. Hadamitzky,et al.  Predictors of antiplatelet response to prasugrel during maintenance treatment , 2015, Platelets.

[12]  P. Morange,et al.  Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel. , 2014, International journal of cardiology.

[13]  I. Xanthopoulou,et al.  Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. , 2014, American heart journal.

[14]  S. James,et al.  The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study. , 2014, Thrombosis research.

[15]  A. Loundou,et al.  Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting. , 2014, The American journal of cardiology.

[16]  H. Schunkert,et al.  Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy—Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial , 2014, Journal of Cardiovascular Translational Research.

[17]  S. James,et al.  Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients , 2013, Journal of Thrombosis and Thrombolysis.

[18]  Jeroen J. Bax,et al.  Third universal definition of myocardial infarction. , 2012, Global heart.

[19]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[20]  R. Califf,et al.  Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. , 2010, International journal of cardiology.

[21]  A. Kastrati,et al.  Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention , 2010, Heart and Vessels.

[22]  P. Barragan,et al.  Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. , 2009, The American journal of cardiology.

[23]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[24]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[25]  A. Kastrati,et al.  Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. , 2007, The American journal of cardiology.

[26]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[27]  G. Stone,et al.  Impact of body mass index on outcomes after percutaneous coronary intervention in patients with acute myocardial infarction. , 2007, The American journal of cardiology.

[28]  E. Topol,et al.  The relationship of obesity to ischemic outcomes following coronary stent placement in contemporary practice , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[29]  J. J. Griffin,et al.  Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. , 2006, American heart journal.

[30]  M. Parikh,et al.  Impact of body mass index on in-hospital outcomes following percutaneous coronary intervention (report from the New York State Angioplasty Registry). , 2004, The American journal of cardiology.

[31]  C. Macaya,et al.  Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? , 2004, The Journal of invasive cardiology.